Abstract
A series of 48 N6-benzyladenosine 5'-uronamide derivatives has been described recently as moderately selective A3 adenosine receptor agonists of nanomolar potency (Gallo-Rodriguez, C. et al. J. Med. Chem. 1994, 37, 636). Quantitative structure activity relationships in this series, including some novel derivatives, have been investigated using a Comparative Molecular Field Analysis (CoMFA), with emphasis on the N6-substituent. The resulting three dimensional pharmacophore model defines the steric and electronic factors which modulate in vitro affinities in binding to rat brain A3 adenosine receptors. The model indicates a positive correlation of affinity with the steric characteristics of the compounds (major factor), particularly toward the 3-position of the benzyl ring of N6-benzyl NECA, and a weak correlation with the electrostatic effects of the N6-substituent. A comparison of active and inactive compounds using volume maps showed that bulk at the 3-position of the benzyl ring of the molecule is conducive to high affinity at A3 receptors, while steric bulk at other positions of the benzyl ring leads to poor binding. t-Boc-amino acid conjugates of a 3-aminobenzyl derivative were synthesized to probe the steric and hydrophobic limitations at that position. We have discovered a subregion of the N6-benzyl binding pocket occupied by a 3-(L-prolylamino) group that is sterically disallowed at A3 receptors and allowed in A1 and A2a receptors. 6-N-Phenylhydrazino and 6-O-phenylhydroxylamino derivatives, incorporating major changes in electrostatic character of the ligand proximal to the purine, were predicted by the CoMFA model to have high A3 affinity. Such analogs were synthesized and found to be well tolerated at the A3 receptor binding site.
MeSH Terms
Adenosine/analogs & derivatives,chemical synthesis,pharmacology
Animals
CHO Cells
Computer Simulation
Cricetinae
Electrochemistry
Kinetics
Models, Molecular
Neostriatum/metabolism
Protein Conformation
Purinergic P1 Receptor Agonists
Rats
Receptors, Purinergic P1/chemistry
Regression Analysis
Structure-Activity Relationship
Chemicals
Purinergic P1 Receptor Agonists
Receptors, Purinergic P1
Adenosine
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Siddiqi S M
Molecular Recognition Section, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Pearlstein R A
Sanders L H
Jacobson K A
References (24)
24 references, click to expand
-
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
J Med Chem. 1992 Feb 7;35(3):407-22
PMID: 1738138
-
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.
J Med Chem. 1994 Mar 4;37(5):636-46
PMID: 8126704
-
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432-6
PMID: 1323836
-
Mapping the N6-region of the adenosine A1 receptor with computer graphics.
Eur J Pharmacol. 1989 Mar 7;172(1):19-27
PMID: 2714369
-
Molecular cloning and characterization of the human A3 adenosine receptor.
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365-9
PMID: 8234299
-
Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.
Mol Pharmacol. 1993 Sep;44(3):524-32
PMID: 8396714
-
Characterization of adenosine receptors in rat brain by (-)[3H]N6-phenylisopropyladenosine.
Naunyn Schmiedebergs Arch Pharmacol. 1980 Sep;313(3):179-87
PMID: 6253840
-
Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart.
Cardiovasc Res. 1994 Jul;28(7):1057-61
PMID: 7954592
-
Adenosine A1 and A2 receptors: structure--function relationships.
Med Res Rev. 1992 Sep;12(5):423-71
PMID: 1513184
-
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.
Mol Pharmacol. 1994 May;45(5):978-82
PMID: 8190112
-
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
J Med Chem. 1994 Oct 14;37(21):3614-21
PMID: 7932588
-
A binding site model and structure-activity relationships for the rat A3 adenosine receptor.
Mol Pharmacol. 1994 Jun;45(6):1101-11
PMID: 8022403
-
Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.
Mol Pharmacol. 1986 Apr;29(4):331-46
PMID: 3010074
-
Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor.
J Biol Chem. 1990 Jan 15;265(2):745-53
PMID: 2295618
-
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.
J Am Chem Soc. 1988 Aug 1;110(18):5959-67
PMID: 22148765
-
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
PMID: 4202581
-
Adenosine A3 receptor stimulation and cerebral ischemia.
Eur J Pharmacol. 1994 Sep 22;263(1-2):59-67
PMID: 7821362
-
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects.
FEBS Lett. 1993 Dec 20;336(1):57-60
PMID: 8262217
-
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells.
J Biol Chem. 1993 Aug 15;268(23):16887-90
PMID: 8349579
-
Adenosine receptors.
J Biol Chem. 1992 Apr 5;267(10):6451-4
PMID: 1551861
-
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.
J Pharmacol Exp Ther. 1989 Dec;251(3):888-93
PMID: 2600819
-
Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat.
Br J Pharmacol. 1993 May;109(1):3-5
PMID: 8495245
-
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors.
J Med Chem. 1985 Sep;28(9):1341-6
PMID: 2993623
-
Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules.
J Med Chem. 1993 Dec 24;36(26):4152-60
PMID: 8277496